Carregant...
Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737
BACKGROUND: Despite the high complete response rates with fludarabine-based regimens, relapse is inevitable in chronic lymphocytic leukemia (CLL). Relapsed patients often acquire 17p deletions [del(17p)], which are closely associated with TP53 mutations. Wild-type p53 upregulates and activates BAX,...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3579224/ https://ncbi.nlm.nih.gov/pubmed/21761401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26360 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|